Kaplan Fox & Kilsheimer LLP Investigates Claims on Behalf of Y-mAbs Investors

NEW YORK, Jan. 19, 2023 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP is continuing its investigation of claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) stock. A complaint has been filed on behalf of investors who purchased shares of Y-mAbs common stock on the open market.

The law firm is looking into potential violations by the company and its officers for possible misleading statements or failure to disclose information that could have an impact on Y-mAbs’ stock price. Investors who suffered financial losses are encouraged to contact Kaplan Fox & Kilsheimer LLP for more information on their legal rights.

Investor Alert

Kaplan Fox & Kilsheimer LLP has notified Y-mAbs investors of a class action lawsuit that has been filed on their behalf. The lawsuit alleges that the company and its executives made false and misleading statements regarding the business, operations, and prospects of Y-mAbs, leading to a drop in the stock price.

Investors who purchased Y-mAbs stock may be eligible to participate in the class action and seek recovery of their losses. Kaplan Fox & Kilsheimer LLP is committed to seeking justice for investors who have been harmed by alleged securities law violations.

Impact on Individuals

For individual investors who purchased Y-mAbs stock, the investigation and class action lawsuit could potentially lead to financial recovery if it is found that the company and its officers engaged in wrongdoing. It is important for affected investors to seek legal counsel to understand their rights and options in this situation.

Impact on the World

From a broader perspective, allegations of securities law violations by companies like Y-mAbs can impact investor confidence in the stock market as a whole. The outcome of this investigation and lawsuit could set a precedent for holding corporations accountable for providing accurate and transparent information to investors.

Conclusion

Kaplan Fox & Kilsheimer LLP’s investigation into Y-mAbs Therapeutics, Inc. and the subsequent class action lawsuit filed on behalf of investors highlight the importance of transparency and accountability in the financial markets. Investors are encouraged to stay informed about their rights and seek legal guidance in cases of potential securities fraud.